nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolmetin—osteoarthritis—Prednisone—psoriatic arthritis	0.349	0.5	CpDpCtD
Tolmetin—osteoarthritis—Methylprednisolone—psoriatic arthritis	0.349	0.5	CpDpCtD
Tolmetin—PTGS2—Triamcinolone—psoriatic arthritis	0.0842	0.377	CbGbCtD
Tolmetin—PTGS2—Betamethasone—psoriatic arthritis	0.0722	0.323	CbGbCtD
Tolmetin—PTGS2—Dexamethasone—psoriatic arthritis	0.042	0.188	CbGbCtD
Tolmetin—SLC22A6—Methotrexate—psoriatic arthritis	0.025	0.112	CbGbCtD
Tolmetin—MPO—IL23-mediated signaling events—IL23R—psoriatic arthritis	0.00393	0.139	CbGpPWpGaD
Tolmetin—MPO—IL23-mediated signaling events—IL23A—psoriatic arthritis	0.00334	0.118	CbGpPWpGaD
Tolmetin—Proteinuria—Auranofin—psoriatic arthritis	0.00215	0.0469	CcSEcCtD
Tolmetin—Protein urine present—Auranofin—psoriatic arthritis	0.00212	0.0462	CcSEcCtD
Tolmetin—Glossitis—Auranofin—psoriatic arthritis	0.00205	0.0447	CcSEcCtD
Tolmetin—CXCL8—ATF-2 transcription factor network—IL23A—psoriatic arthritis	0.0017	0.0603	CbGpPWpGaD
Tolmetin—MPO—IL23-mediated signaling events—IL17A—psoriatic arthritis	0.00156	0.0553	CbGpPWpGaD
Tolmetin—MPO—IL23-mediated signaling events—IL12B—psoriatic arthritis	0.00145	0.0514	CbGpPWpGaD
Tolmetin—Gastrointestinal haemorrhage—Auranofin—psoriatic arthritis	0.00137	0.0299	CcSEcCtD
Tolmetin—CXCL8—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.00113	0.0399	CbGpPWpGaD
Tolmetin—Weight decreased—Auranofin—psoriatic arthritis	0.00107	0.0234	CcSEcCtD
Tolmetin—Stomatitis—Auranofin—psoriatic arthritis	0.00103	0.0225	CcSEcCtD
Tolmetin—Haematuria—Auranofin—psoriatic arthritis	0.00101	0.022	CcSEcCtD
Tolmetin—Agranulocytosis—Auranofin—psoriatic arthritis	0.000987	0.0215	CcSEcCtD
Tolmetin—Visual impairment—Auranofin—psoriatic arthritis	0.000915	0.0199	CcSEcCtD
Tolmetin—TDO2—Monoamine Transport—TNF—psoriatic arthritis	0.000865	0.0306	CbGpPWpGaD
Tolmetin—MPO—IL23-mediated signaling events—NOS2—psoriatic arthritis	0.000815	0.0288	CbGpPWpGaD
Tolmetin—Flatulence—Auranofin—psoriatic arthritis	0.000814	0.0177	CcSEcCtD
Tolmetin—MPO—Vitamin B12 Metabolism—CRP—psoriatic arthritis	0.000691	0.0244	CbGpPWpGaD
Tolmetin—CXCL8—Allograft Rejection—HLA-C—psoriatic arthritis	0.000691	0.0244	CbGpPWpGaD
Tolmetin—CXCL8—Allograft Rejection—IL13—psoriatic arthritis	0.000687	0.0243	CbGpPWpGaD
Tolmetin—CXCL8—Glucocorticoid receptor regulatory network—IL13—psoriatic arthritis	0.000667	0.0236	CbGpPWpGaD
Tolmetin—Thrombocytopenia—Auranofin—psoriatic arthritis	0.00066	0.0144	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—IL17A—psoriatic arthritis	0.000632	0.0223	CbGpPWpGaD
Tolmetin—PTGS1—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000623	0.022	CbGpPWpGaD
Tolmetin—Dyspepsia—Auranofin—psoriatic arthritis	0.000594	0.0129	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—IL12B—psoriatic arthritis	0.000588	0.0208	CbGpPWpGaD
Tolmetin—PTGS2—Fluocinonide—Methylprednisolone—psoriatic arthritis	0.00058	0.159	CbGdCrCtD
Tolmetin—Constipation—Auranofin—psoriatic arthritis	0.000577	0.0126	CcSEcCtD
Tolmetin—PTGS2—Fluocinonide—Betamethasone—psoriatic arthritis	0.000571	0.156	CbGdCrCtD
Tolmetin—PTGS2—Fluocinonide—Dexamethasone—psoriatic arthritis	0.000571	0.156	CbGdCrCtD
Tolmetin—MPO—Folate Metabolism—CRP—psoriatic arthritis	0.000562	0.0199	CbGpPWpGaD
Tolmetin—PTGS2—Fluocinonide—Triamcinolone—psoriatic arthritis	0.000558	0.153	CbGdCrCtD
Tolmetin—Gastrointestinal pain—Auranofin—psoriatic arthritis	0.000551	0.012	CcSEcCtD
Tolmetin—Urticaria—Auranofin—psoriatic arthritis	0.000536	0.0117	CcSEcCtD
Tolmetin—Abdominal pain—Auranofin—psoriatic arthritis	0.000533	0.0116	CcSEcCtD
Tolmetin—CXCL8—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.000511	0.0181	CbGpPWpGaD
Tolmetin—PTGS2—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.000495	0.0175	CbGpPWpGaD
Tolmetin—Cardiac failure congestive—Prednisolone—psoriatic arthritis	0.000482	0.0105	CcSEcCtD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000479	0.0169	CbGpPWpGaD
Tolmetin—Visual disturbance—Prednisolone—psoriatic arthritis	0.000462	0.0101	CcSEcCtD
Tolmetin—Diarrhoea—Auranofin—psoriatic arthritis	0.000461	0.0101	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Prednisolone—psoriatic arthritis	0.000452	0.00985	CcSEcCtD
Tolmetin—Vascular purpura—Triamcinolone—psoriatic arthritis	0.00045	0.0098	CcSEcCtD
Tolmetin—MPO—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000447	0.0158	CbGpPWpGaD
Tolmetin—Cardiac failure congestive—Triamcinolone—psoriatic arthritis	0.000444	0.00967	CcSEcCtD
Tolmetin—Cardiac failure congestive—Methylprednisolone—psoriatic arthritis	0.000443	0.00965	CcSEcCtD
Tolmetin—CXCL8—EBV LMP1 signaling—TNF—psoriatic arthritis	0.000439	0.0155	CbGpPWpGaD
Tolmetin—Vomiting—Auranofin—psoriatic arthritis	0.000429	0.00935	CcSEcCtD
Tolmetin—Purpura—Triamcinolone—psoriatic arthritis	0.000417	0.0091	CcSEcCtD
Tolmetin—Proteinuria—Methotrexate—psoriatic arthritis	0.000417	0.00908	CcSEcCtD
Tolmetin—CXCL8—ATF-2 transcription factor network—NOS2—psoriatic arthritis	0.000416	0.0147	CbGpPWpGaD
Tolmetin—Anaphylactoid reaction—Triamcinolone—psoriatic arthritis	0.000416	0.00906	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Methylprednisolone—psoriatic arthritis	0.000415	0.00904	CcSEcCtD
Tolmetin—Protein urine present—Methotrexate—psoriatic arthritis	0.000411	0.00895	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—HLA-B—psoriatic arthritis	0.000409	0.0144	CbGpPWpGaD
Tolmetin—MPO—IL23-mediated signaling events—TNF—psoriatic arthritis	0.000404	0.0143	CbGpPWpGaD
Tolmetin—Cardiac failure congestive—Dexamethasone—psoriatic arthritis	0.000403	0.00877	CcSEcCtD
Tolmetin—Cardiac failure congestive—Betamethasone—psoriatic arthritis	0.000403	0.00877	CcSEcCtD
Tolmetin—Nausea—Auranofin—psoriatic arthritis	0.000401	0.00873	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—IL13—psoriatic arthritis	0.000398	0.0141	CbGpPWpGaD
Tolmetin—Glossitis—Methotrexate—psoriatic arthritis	0.000397	0.00866	CcSEcCtD
Tolmetin—Visual disturbance—Betamethasone—psoriatic arthritis	0.000385	0.0084	CcSEcCtD
Tolmetin—Visual disturbance—Dexamethasone—psoriatic arthritis	0.000385	0.0084	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Betamethasone—psoriatic arthritis	0.000377	0.00822	CcSEcCtD
Tolmetin—Anaphylactoid reaction—Dexamethasone—psoriatic arthritis	0.000377	0.00822	CcSEcCtD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.000374	0.0132	CbGpPWpGaD
Tolmetin—Vascular purpura—Prednisone—psoriatic arthritis	0.000355	0.00775	CcSEcCtD
Tolmetin—Cardiac failure congestive—Prednisone—psoriatic arthritis	0.000351	0.00764	CcSEcCtD
Tolmetin—PTGS2—Fluticasone Propionate—Methylprednisolone—psoriatic arthritis	0.00035	0.0957	CbGdCrCtD
Tolmetin—CXCL8—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000346	0.0122	CbGpPWpGaD
Tolmetin—PTGS2—Fluticasone Propionate—Dexamethasone—psoriatic arthritis	0.000345	0.0942	CbGdCrCtD
Tolmetin—PTGS2—Fluticasone Propionate—Betamethasone—psoriatic arthritis	0.000345	0.0942	CbGdCrCtD
Tolmetin—Weight increased—Prednisolone—psoriatic arthritis	0.000344	0.0075	CcSEcCtD
Tolmetin—PTGS2—Fluticasone Propionate—Triamcinolone—psoriatic arthritis	0.000337	0.0921	CbGdCrCtD
Tolmetin—Purpura—Prednisone—psoriatic arthritis	0.00033	0.00719	CcSEcCtD
Tolmetin—Gastrointestinal haemorrhage—Prednisone—psoriatic arthritis	0.000318	0.00693	CcSEcCtD
Tolmetin—Weight increased—Triamcinolone—psoriatic arthritis	0.000316	0.0069	CcSEcCtD
Tolmetin—Weight increased—Methylprednisolone—psoriatic arthritis	0.000316	0.00688	CcSEcCtD
Tolmetin—MPO—Vitamin B12 Metabolism—TNF—psoriatic arthritis	0.000313	0.0111	CbGpPWpGaD
Tolmetin—Lymphadenopathy—Methotrexate—psoriatic arthritis	0.000311	0.00679	CcSEcCtD
Tolmetin—Epistaxis—Triamcinolone—psoriatic arthritis	0.000292	0.00637	CcSEcCtD
Tolmetin—Visual impairment—Prednisolone—psoriatic arthritis	0.000292	0.00636	CcSEcCtD
Tolmetin—Weight increased—Betamethasone—psoriatic arthritis	0.000287	0.00626	CcSEcCtD
Tolmetin—Weight increased—Dexamethasone—psoriatic arthritis	0.000287	0.00626	CcSEcCtD
Tolmetin—Weight decreased—Betamethasone—psoriatic arthritis	0.000285	0.00622	CcSEcCtD
Tolmetin—Weight decreased—Dexamethasone—psoriatic arthritis	0.000285	0.00622	CcSEcCtD
Tolmetin—PTGS1—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.000282	0.00997	CbGpPWpGaD
Tolmetin—Visual disturbance—Methotrexate—psoriatic arthritis	0.00028	0.00611	CcSEcCtD
Tolmetin—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	0.000277	0.00978	CbGpPWpGaD
Tolmetin—Anaphylactoid reaction—Methotrexate—psoriatic arthritis	0.000275	0.00598	CcSEcCtD
Tolmetin—Visual impairment—Methylprednisolone—psoriatic arthritis	0.000268	0.00583	CcSEcCtD
Tolmetin—MPO—Folate Metabolism—TNF—psoriatic arthritis	0.000255	0.009	CbGpPWpGaD
Tolmetin—Weight increased—Prednisone—psoriatic arthritis	0.00025	0.00545	CcSEcCtD
Tolmetin—Weight decreased—Prednisone—psoriatic arthritis	0.000249	0.00542	CcSEcCtD
Tolmetin—Visual impairment—Betamethasone—psoriatic arthritis	0.000243	0.0053	CcSEcCtD
Tolmetin—Visual impairment—Dexamethasone—psoriatic arthritis	0.000243	0.0053	CcSEcCtD
Tolmetin—Toxic epidermal necrolysis—Methotrexate—psoriatic arthritis	0.000239	0.00521	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—NOS2—psoriatic arthritis	0.000239	0.00845	CbGpPWpGaD
Tolmetin—CXCL8—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriatic arthritis	0.000236	0.00833	CbGpPWpGaD
Tolmetin—PTGS2—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.000224	0.00792	CbGpPWpGaD
Tolmetin—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.00022	0.0048	CcSEcCtD
Tolmetin—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.000215	0.00469	CcSEcCtD
Tolmetin—Oedema—Prednisolone—psoriatic arthritis	0.000215	0.00469	CcSEcCtD
Tolmetin—Dysuria—Methotrexate—psoriatic arthritis	0.000215	0.00468	CcSEcCtD
Tolmetin—Drowsiness—Methotrexate—psoriatic arthritis	0.000205	0.00446	CcSEcCtD
Tolmetin—MPO—Selenium Micronutrient Network—TNF—psoriatic arthritis	0.000202	0.00715	CbGpPWpGaD
Tolmetin—Renal failure—Methotrexate—psoriatic arthritis	0.000201	0.00439	CcSEcCtD
Tolmetin—Stomatitis—Methotrexate—psoriatic arthritis	0.0002	0.00435	CcSEcCtD
Tolmetin—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000198	0.00431	CcSEcCtD
Tolmetin—Oedema—Triamcinolone—psoriatic arthritis	0.000198	0.00431	CcSEcCtD
Tolmetin—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000197	0.0043	CcSEcCtD
Tolmetin—Haematuria—Methotrexate—psoriatic arthritis	0.000195	0.00426	CcSEcCtD
Tolmetin—Epistaxis—Methotrexate—psoriatic arthritis	0.000193	0.00421	CcSEcCtD
Tolmetin—Agranulocytosis—Methotrexate—psoriatic arthritis	0.000191	0.00416	CcSEcCtD
Tolmetin—Hepatitis—Methotrexate—psoriatic arthritis	0.000184	0.00401	CcSEcCtD
Tolmetin—PTGS1—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000183	0.00646	CbGpPWpGaD
Tolmetin—Oedema—Dexamethasone—psoriatic arthritis	0.000179	0.00391	CcSEcCtD
Tolmetin—Oedema—Betamethasone—psoriatic arthritis	0.000179	0.00391	CcSEcCtD
Tolmetin—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000179	0.00391	CcSEcCtD
Tolmetin—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000179	0.00391	CcSEcCtD
Tolmetin—Visual impairment—Methotrexate—psoriatic arthritis	0.000177	0.00386	CcSEcCtD
Tolmetin—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000176	0.00383	CcSEcCtD
Tolmetin—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000176	0.00383	CcSEcCtD
Tolmetin—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000174	0.00379	CcSEcCtD
Tolmetin—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000174	0.00379	CcSEcCtD
Tolmetin—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000174	0.00379	CcSEcCtD
Tolmetin—Tinnitus—Methotrexate—psoriatic arthritis	0.000171	0.00374	CcSEcCtD
Tolmetin—Urticaria—Prednisolone—psoriatic arthritis	0.000171	0.00372	CcSEcCtD
Tolmetin—CXCL8—Allograft Rejection—TNF—psoriatic arthritis	0.000164	0.00578	CbGpPWpGaD
Tolmetin—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000161	0.00352	CcSEcCtD
Tolmetin—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000158	0.00344	CcSEcCtD
Tolmetin—Dyspepsia—Betamethasone—psoriatic arthritis	0.000158	0.00344	CcSEcCtD
Tolmetin—Urticaria—Triamcinolone—psoriatic arthritis	0.000157	0.00342	CcSEcCtD
Tolmetin—Urticaria—Methylprednisolone—psoriatic arthritis	0.000157	0.00342	CcSEcCtD
Tolmetin—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000156	0.00341	CcSEcCtD
Tolmetin—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000156	0.00341	CcSEcCtD
Tolmetin—Oedema—Prednisone—psoriatic arthritis	0.000156	0.00341	CcSEcCtD
Tolmetin—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000156	0.0034	CcSEcCtD
Tolmetin—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000147	0.0032	CcSEcCtD
Tolmetin—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000147	0.0032	CcSEcCtD
Tolmetin—PTGS2—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000145	0.00513	CbGpPWpGaD
Tolmetin—Urticaria—Betamethasone—psoriatic arthritis	0.000143	0.00311	CcSEcCtD
Tolmetin—Urticaria—Dexamethasone—psoriatic arthritis	0.000143	0.00311	CcSEcCtD
Tolmetin—Dizziness—Prednisolone—psoriatic arthritis	0.000142	0.0031	CcSEcCtD
Tolmetin—Asthenia—Triamcinolone—psoriatic arthritis	0.000142	0.00309	CcSEcCtD
Tolmetin—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000142	0.00309	CcSEcCtD
Tolmetin—Body temperature increased—Betamethasone—psoriatic arthritis	0.000142	0.00309	CcSEcCtD
Tolmetin—Abdominal pain—Betamethasone—psoriatic arthritis	0.000142	0.00309	CcSEcCtD
Tolmetin—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000142	0.00309	CcSEcCtD
Tolmetin—Asthenia—Methylprednisolone—psoriatic arthritis	0.000142	0.00309	CcSEcCtD
Tolmetin—Dyspepsia—Prednisone—psoriatic arthritis	0.000138	0.003	CcSEcCtD
Tolmetin—Chest pain—Methotrexate—psoriatic arthritis	0.000136	0.00297	CcSEcCtD
Tolmetin—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000135	0.00294	CcSEcCtD
Tolmetin—Headache—Prednisolone—psoriatic arthritis	0.000135	0.00294	CcSEcCtD
Tolmetin—Constipation—Prednisone—psoriatic arthritis	0.000134	0.00291	CcSEcCtD
Tolmetin—CXCL8—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000133	0.00471	CbGpPWpGaD
Tolmetin—Dizziness—Triamcinolone—psoriatic arthritis	0.000131	0.00285	CcSEcCtD
Tolmetin—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000131	0.00285	CcSEcCtD
Tolmetin—Dizziness—Methylprednisolone—psoriatic arthritis	0.00013	0.00284	CcSEcCtD
Tolmetin—Asthenia—Betamethasone—psoriatic arthritis	0.000129	0.00281	CcSEcCtD
Tolmetin—Asthenia—Dexamethasone—psoriatic arthritis	0.000129	0.00281	CcSEcCtD
Tolmetin—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000128	0.00279	CcSEcCtD
Tolmetin—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000128	0.00278	CcSEcCtD
Tolmetin—Nausea—Prednisolone—psoriatic arthritis	0.000128	0.00278	CcSEcCtD
Tolmetin—Vomiting—Triamcinolone—psoriatic arthritis	0.000126	0.00274	CcSEcCtD
Tolmetin—Vomiting—Methylprednisolone—psoriatic arthritis	0.000125	0.00273	CcSEcCtD
Tolmetin—Urticaria—Prednisone—psoriatic arthritis	0.000124	0.00271	CcSEcCtD
Tolmetin—Headache—Triamcinolone—psoriatic arthritis	0.000124	0.0027	CcSEcCtD
Tolmetin—Headache—Methylprednisolone—psoriatic arthritis	0.000124	0.00269	CcSEcCtD
Tolmetin—Body temperature increased—Prednisone—psoriatic arthritis	0.000124	0.00269	CcSEcCtD
Tolmetin—Abdominal pain—Prednisone—psoriatic arthritis	0.000124	0.00269	CcSEcCtD
Tolmetin—Diarrhoea—Betamethasone—psoriatic arthritis	0.000123	0.00268	CcSEcCtD
Tolmetin—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000123	0.00268	CcSEcCtD
Tolmetin—Dizziness—Betamethasone—psoriatic arthritis	0.000119	0.00259	CcSEcCtD
Tolmetin—Dizziness—Dexamethasone—psoriatic arthritis	0.000119	0.00259	CcSEcCtD
Tolmetin—CXCL8—Spinal Cord Injury—TNF—psoriatic arthritis	0.000119	0.00419	CbGpPWpGaD
Tolmetin—Nausea—Triamcinolone—psoriatic arthritis	0.000117	0.00256	CcSEcCtD
Tolmetin—Nausea—Methylprednisolone—psoriatic arthritis	0.000117	0.00255	CcSEcCtD
Tolmetin—Somnolence—Methotrexate—psoriatic arthritis	0.000116	0.00253	CcSEcCtD
Tolmetin—Dyspepsia—Methotrexate—psoriatic arthritis	0.000115	0.00251	CcSEcCtD
Tolmetin—Vomiting—Dexamethasone—psoriatic arthritis	0.000114	0.00249	CcSEcCtD
Tolmetin—Vomiting—Betamethasone—psoriatic arthritis	0.000114	0.00249	CcSEcCtD
Tolmetin—Headache—Betamethasone—psoriatic arthritis	0.000112	0.00245	CcSEcCtD
Tolmetin—Headache—Dexamethasone—psoriatic arthritis	0.000112	0.00245	CcSEcCtD
Tolmetin—Asthenia—Prednisone—psoriatic arthritis	0.000112	0.00244	CcSEcCtD
Tolmetin—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.00011	0.0039	CbGpPWpGaD
Tolmetin—Diarrhoea—Prednisone—psoriatic arthritis	0.000107	0.00233	CcSEcCtD
Tolmetin—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000107	0.00233	CcSEcCtD
Tolmetin—Nausea—Betamethasone—psoriatic arthritis	0.000107	0.00232	CcSEcCtD
Tolmetin—Nausea—Dexamethasone—psoriatic arthritis	0.000107	0.00232	CcSEcCtD
Tolmetin—PTGS2—Spinal Cord Injury—NOS2—psoriatic arthritis	0.000105	0.0037	CbGpPWpGaD
Tolmetin—CXCL8—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000104	0.00368	CbGpPWpGaD
Tolmetin—Urticaria—Methotrexate—psoriatic arthritis	0.000104	0.00226	CcSEcCtD
Tolmetin—Dizziness—Prednisone—psoriatic arthritis	0.000103	0.00225	CcSEcCtD
Tolmetin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriatic arthritis	0.000103	0.00365	CbGpPWpGaD
Tolmetin—Body temperature increased—Methotrexate—psoriatic arthritis	0.000103	0.00225	CcSEcCtD
Tolmetin—Abdominal pain—Methotrexate—psoriatic arthritis	0.000103	0.00225	CcSEcCtD
Tolmetin—CXCL8—Metabolism of proteins—ACE—psoriatic arthritis	0.000101	0.00358	CbGpPWpGaD
Tolmetin—Vomiting—Prednisone—psoriatic arthritis	9.94e-05	0.00217	CcSEcCtD
Tolmetin—Headache—Prednisone—psoriatic arthritis	9.79e-05	0.00213	CcSEcCtD
Tolmetin—CXCL8—SIDS Susceptibility Pathways—TNF—psoriatic arthritis	9.49e-05	0.00335	CbGpPWpGaD
Tolmetin—Asthenia—Methotrexate—psoriatic arthritis	9.37e-05	0.00204	CcSEcCtD
Tolmetin—Nausea—Prednisone—psoriatic arthritis	9.28e-05	0.00202	CcSEcCtD
Tolmetin—Diarrhoea—Methotrexate—psoriatic arthritis	8.94e-05	0.00195	CcSEcCtD
Tolmetin—Dizziness—Methotrexate—psoriatic arthritis	8.64e-05	0.00188	CcSEcCtD
Tolmetin—Vomiting—Methotrexate—psoriatic arthritis	8.3e-05	0.00181	CcSEcCtD
Tolmetin—PTGS1—Selenium Micronutrient Network—TNF—psoriatic arthritis	8.28e-05	0.00293	CbGpPWpGaD
Tolmetin—Headache—Methotrexate—psoriatic arthritis	8.18e-05	0.00178	CcSEcCtD
Tolmetin—Nausea—Methotrexate—psoriatic arthritis	7.76e-05	0.00169	CcSEcCtD
Tolmetin—PTGS2—Selenium Micronutrient Network—TNF—psoriatic arthritis	6.57e-05	0.00232	CbGpPWpGaD
Tolmetin—PTGS2—Spinal Cord Injury—TNF—psoriatic arthritis	5.2e-05	0.00184	CbGpPWpGaD
Tolmetin—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	3.53e-05	0.00125	CbGpPWpGaD
Tolmetin—PTGS2—Disease—NOS2—psoriatic arthritis	1.58e-05	0.000559	CbGpPWpGaD
